Cargando…

Clinical Characteristics and Outcome of Patients with Neuroblastoma Presenting Genomic Amplification of Loci Other than MYCN

BACKGROUND: Somatically acquired genomic alterations with MYCN amplification (MNA) are key features of neuroblastoma (NB), the most common extra-cranial malignant tumour of childhood. Little is known about the frequency, clinical characteristics and outcome of NBs harbouring genomic amplification(s)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guimier, Anne, Ferrand, Sandrine, Pierron, Gaëlle, Couturier, Jérôme, Janoueix-Lerosey, Isabelle, Combaret, Valérie, Mosseri, Véronique, Thebaud, Estelle, Gambart, Marion, Plantaz, Dominique, Marabelle, Aurélien, Coze, Carole, Rialland, Xavier, Fasola, Sylvie, Lapouble, Eve, Fréneaux, Paul, Peuchmaur, Michel, Michon, Jean, Delattre, Olivier, Schleiermacher, Gudrun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094484/ https://www.ncbi.nlm.nih.gov/pubmed/25013904 http://dx.doi.org/10.1371/journal.pone.0101990

Ejemplares similares

Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival
por: Brisse, Hervé J., et al.
Publicado: (2017)

Detection of tumor ALK status in neuroblastoma patients using peripheral blood
por: Combaret, Valérie, et al.
Publicado: (2015)

Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification
por: Schleiermacher, G, et al.
Publicado: (2007)

Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma
por: Bellini, Angela, et al.
Publicado: (2019)

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)
por: Schleiermacher, G, et al.
Publicado: (2011)

Breakpoint Features of Genomic Rearrangements in Neuroblastoma with Unbalanced Translocations and Chromothripsis
por: Boeva, Valentina, et al.
Publicado: (2013)

Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma
por: Costa, Ana, et al.
Publicado: (2022)

Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data
por: Boeva, Valentina, et al.
Publicado: (2012)

Learning smoothing models of copy number profiles using breakpoint annotations
por: Hocking, Toby Dylan, et al.
Publicado: (2013)

QuantumClone: clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction
por: Deveau, Paul, et al.
Publicado: (2018)

ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations
por: Durand, Simon, et al.
Publicado: (2019)

Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology
por: Minard, V, et al.
Publicado: (2000)

Activated ALK signals through the ERK–ETV5–RET pathway to drive neuroblastoma oncogenesis
por: Lopez-Delisle, Lucille, et al.
Publicado: (2018)

High CD44 expression is not a prognosis marker in patients with high-risk neuroblastoma
por: Louis-Brennetot, Caroline, et al.
Publicado: (2020)

Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma
por: Cazes, Alex, et al.
Publicado: (2014)

Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy
por: Rubie, H, et al.
Publicado: (2003)

SegAnnDB: interactive Web-based genomic segmentation
por: Hocking, Toby D., et al.
Publicado: (2014)

Plasticity in Neuroblastoma Cell Identity Defines a Noradrenergic-to-Mesenchymal Transition (NMT)
por: Gautier, Margot, et al.
Publicado: (2021)

Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma
por: Thirant, Cécile, et al.
Publicado: (2023)

Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group
por: Ambros, Inge M., et al.
Publicado: (2020)

The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivation
por: Han, Zhi-Yan, et al.
Publicado: (2016)

Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells
por: Montavon, Gisèle, et al.
Publicado: (2014)

Control-free calling of copy number alterations in deep-sequencing data using GC-content normalization
por: Boeva, Valentina, et al.
Publicado: (2011)

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
por: Berbegall, Ana P., et al.
Publicado: (2018)

SVDetect: a tool to identify genomic structural variations from paired-end and mate-pair sequencing data
por: Zeitouni, Bruno, et al.
Publicado: (2010)

Incidence and prognostic value of tumour cells detected by RT–PCR in peripheral blood stem cell collections from patients with Ewing tumour
por: Vermeulen, J, et al.
Publicado: (2006)

MYCN and the epigenome
por: He, Stanley, et al.
Publicado: (2013)

Cell-Free DNA Extracted from CSF for the Molecular Diagnosis of Pediatric Embryonal Brain Tumors
por: Chicard, Mathieu, et al.
Publicado: (2023)

SV-Bay: structural variant detection in cancer genomes using a Bayesian approach with correction for GC-content and read mappability
por: Iakovishina, Daria, et al.
Publicado: (2016)

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification
por: Defferrari, R, et al.
Publicado: (2015)

Suprarenal Masses in Very Young Infants: Is It Safe to Watch and Wait? Report of a SIOPEN Observational Study Results
por: Papadakis, Vassilios, et al.
Publicado: (2022)

High Cyclin E Staining Index in Blastemal, Stromal or Epithelial Cells Is Correlated with Tumor Aggressiveness in Patients with Nephroblastoma
por: Berrebi, Dominique, et al.
Publicado: (2008)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020)

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)

HMCan-diff: a method to detect changes in histone modifications in cells with different genetic characteristics
por: Ashoor, Haitham, et al.
Publicado: (2017)

BET and CDK Inhibition Reveal Differences in the Proliferation Control of Sympathetic Ganglion Neuroblasts and Adrenal Chromaffin Cells
por: Sriha, Jessica, et al.
Publicado: (2022)

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification
por: Huang, Can, et al.
Publicado: (2020)

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma
por: Zhang, Hai-Feng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0g9o6fvns7038mkrdia17v7bcf